SOAT1 and acute lymphoblastic leukemia: Activation of the JAK-STAT pathway occurs in approximately 64% of Ph-like ALL patients, including 42% with CRLF2 rearrangements and 22% with non-CRLF2 rearrangements, both of which are therapeutically targeted by JAK inhibitors (1).